Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver
about
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.Recent advances in pharmacokinetic extrapolation from preclinical data to humans.Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors.Large-scale analysis of adeno-associated virus vector integration sites in normal human cells.Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) modelsModelling approaches to dose estimation in childrenContent and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo.Calorie Restriction Increases P-Glycoprotein and Decreases Intestinal Absorption of Digoxin in MiceModeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearanceEnhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesionsUse of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.Modelling and PBPK simulation in drug discovery.Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from P. fruticosa.Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cellsIn vitro-in vivo correlation of hepatobiliary drug clearance in humans.Characterisation of artemisinin-chloroquinoline hybrids for potential metabolic liabilities.A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions.The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.Quantifying gut wall metabolism: methodology matters.Chromosomal integration of adenoviral vector DNA in vivo.Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs.Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog.Hepatic and intestinal CYP3A expression and activity in broilers.The Effects of Aging on Hepatic Microsomal Scaling Factor and Hepatocellularity Number in the Horse.A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model.Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.Storage stability study of porcine hepatic and intestinal cytochrome P450 isoenzymes by use of a newly developed and fully validated highly sensitive HPLC-MS/MS method.Microsomal protein per gram of liver (MPPGL) in paediatric biliary atresia patients.CYP2D6 protein level is the major contributor to inter-individual variability in CYP2D6-mediated drug metabolism in healthy human liver tissue.
P2860
Q31044030-D5677717-2DFD-4882-A551-E8D9EEFB9862Q31049599-80B7DD57-0203-4DBC-ACBB-32FC01B97E90Q33442896-3D5C765D-BFBF-4D77-B1A4-AE67CB905CB4Q33460512-AF7106FE-9387-4D0F-B588-2E8546CA47C8Q33628703-4365D12D-673D-48B6-AEED-E1667B591F19Q33930318-BC43C425-47CA-4AC0-B08C-5273820B9034Q34035243-03EA4594-7CAD-428F-86FE-EE1AD9D2B9EAQ34933094-E39EF500-809A-4FED-A52A-A5B87AF8D8A3Q34990717-285FB1B6-72E6-44B0-9EC8-A16662735623Q35753588-73E22873-4E0C-460A-B89F-6420494A6731Q35827045-8A7B1794-4FB8-40D2-B004-7F99AB3D82AEQ36346340-61CE66EB-2CE6-40C2-B90D-05E57FA5255AQ36618672-46ED7E13-347D-4F88-ACC6-BA0950AB6FDCQ36702459-71E0B4B3-9E1B-4D5A-AE00-E54496B4E353Q36924729-95BFF924-13B4-4E37-9EA0-E9BF49FCAC26Q37033738-73637D0C-D92E-4CD8-BEDC-B77916430385Q37188002-F4C0DEA8-E1E3-4C1F-A218-A203CC0A114EQ37413064-5BD983DC-A22C-437F-8C8A-B14D0CC9AC81Q37600381-EA152A5B-07A9-4DA6-B61A-D67865F85323Q38038547-BDDE61BF-4267-440F-929D-454C81213019Q39624983-93C05BF9-493D-4670-81A2-7807E9B116C5Q39732707-79C6980D-2F95-42CF-B1ED-1116A490DFA2Q39873984-633D5964-C438-4F1D-AD30-27287913B8A1Q40250598-135368B3-B9C5-4C2D-A35F-42CAF2F43ED9Q40575964-A1AAE1B8-CA4A-47DE-8E21-EBEF876B53D0Q41072555-AFDDBF93-8773-485F-9DA0-38DB0204F946Q41118521-0150235E-3202-4C00-BC77-DCADB1AB5A76Q42289931-EC6D23A8-F5B9-4288-8FAF-B0A151E2C0DEQ42428093-0B756D05-99F9-49A9-B031-96F8BA2724B1Q44677954-3320D831-AF67-4762-8D64-7E1A01F28236Q45151691-0346984F-EDDB-4054-A4A6-447C7080ED52Q45908303-7DC8D4A1-947C-4B42-9E24-70C0E955412EQ46245362-92A1EBB9-B6FA-4C4F-A67C-05A9F3CCEAAAQ46249337-2E849CC0-FFE4-4A49-A004-65D4531AD51CQ48010621-B8AB7B39-5DBE-4ED6-8F6E-C74EF74132D7Q48276802-F9874AF9-9CE0-412B-9CA9-76AA28AFC8A5Q48463862-E1077874-EA83-432E-93C6-50263AB8D3D5Q49033457-1F6A63E6-E807-4027-80FD-29D1E7A30ABDQ49081907-BFBC9D63-99A4-4EDE-84E5-1283C9D12879Q49933391-F76380BD-2116-48E2-BC2F-F8F6054607EE
P2860
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Inter-individual variability i ...... ocellularity per gram of liver
@ast
Inter-individual variability i ...... ocellularity per gram of liver
@en
type
label
Inter-individual variability i ...... ocellularity per gram of liver
@ast
Inter-individual variability i ...... ocellularity per gram of liver
@en
prefLabel
Inter-individual variability i ...... ocellularity per gram of liver
@ast
Inter-individual variability i ...... ocellularity per gram of liver
@en
P2093
P2860
P1476
Inter-individual variability i ...... ocellularity per gram of liver
@en
P2093
A Rostami-Hodjegan
G T Tucker
Z E Wilson
P2860
P304
P356
10.1046/J.1365-2125.2003.01881.X
P407
P577
2003-10-01T00:00:00Z